Actively Recruiting

Phase Not Applicable
Age: 25Years - 65Years
All Genders
NCT05287867

Trial for Treating Painful Degenerative Disc Disease

Led by Regenexx, LLC · Updated on 2025-04-06

42

Participants Needed

2

Research Sites

242 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To evaluate and compare two platelet-based treatments of the functional spinal unit spaced 4 weeks apart to sham procedures for the treatment of degenerative disc disease.

CONDITIONS

Official Title

Trial for Treating Painful Degenerative Disc Disease

Who Can Participate

Age: 25Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Voluntary signature of the IRB approved Informed Consent
  • Male or Female aged 25 to 65
  • Degenerative disc disease affecting up to 3 levels without significant spondylolisthesis (grade 1 with ≤10% vertebral body slip)
  • Chronic back and/or leg pain lasting at least 6 months that did not improve with conservative treatments like NSAIDs or physical therapy
  • MRI and physical exam consistent with painful degenerative disc disease
  • Failure of treatments such as epidural steroid injection, facet injection, medial branch block, radiofrequency ablation, or physical therapy
  • Evidence of instability related to degenerative changes on MRI, flexion-extension x-ray, or physical deformity
  • Candidate for lumbar surgery (fusion, decompression, etc.) as specified
  • Independent, ambulatory, and able to comply with all post-operative evaluations and visits
Not Eligible

You will not qualify if you...

  • More than moderate central canal or foraminal stenosis
  • Current smoker or quit less than 6 weeks ago
  • Untreated psychological conditions contributing to chronic pain (e.g., depression, chronic pain syndrome)
  • Epidural steroid injection within the past 8 weeks
  • Degenerative scoliosis with a Cobb angle over 10 degrees
  • Previous Regenexx lumbar procedure
  • Unable to stand longer than 30 minutes
  • Inflammatory or autoimmune diseases (e.g., rheumatoid arthritis, lupus, psoriatic arthritis, polymyalgia, polymyositis, gout, pseudogout)
  • Severe neurogenic inflammation of cutaneous nerves
  • Workers' compensation case
  • Involved in health-related litigation
  • Pregnant
  • Bleeding disorders
  • Taking anticoagulant or immunosuppressive medications
  • Allergy or intolerance to study medication
  • Chronic opioid use
  • Drug abuse within 6 months prior to treatment
  • Central sensitization
  • Hypermobile or Ehlers-Danlos syndrome
  • Any other condition that investigator believes precludes enrollment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Centeno-Schultz Clinic

Broomfield, Colorado, United States, 80021

Actively Recruiting

2

Centeno-Schultz Clinic

Lone Tree, Colorado, United States, 80124

Actively Recruiting

Loading map...

Research Team

E

Ehren Dodson, PhD

CONTACT

N

Neven Steinmetz, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here